Pfizer shares could trend higher in H2 after Gilead Sciences deal
The US-based drug maker could see its shares trend higher in the second half of 2020 after signing a multi-year agreement to make Gilead Sciences’ coronavirus treatment remdesivir.
Pfizer shares have been on a roller coaster ride this year, but the stock has climbed more than 19% since the tail end of June and could finish 2020 in a strong position after signing a multi-year agreement to make Gilead Sciences’ coronavirus treatment remdesivir.
Gilead Sciences is reportedly looking to produce enough of its antiviral drug to treat 2 million patients by the end of 2020, with the drug maker agreeing to send all of its supply of remdesivir to US hospitals throughout September.
Pfizer meanwhile is working with German biotech company BioNTech to develop a coronavirus vaccine, with the race to find a cure heating up after major breakthroughs from AstraZeneca’s partnership with Oxford University last month.
Pfizer is trading at $38.48 per share at the time of publication, with the stock down 1% year-to-date.
Pfizer reports ‘resilient’ earnings amid Covid-19 crisis
Last week, the US-based drug maker saw its shares lifted by better-than-expected second quarter (Q2) earnings and upgraded outlook for H2 2020.
However, the company did see profits fall 32% as demand for many of its drugs fell as a result of the upheaval created by Covid-19. Revenue meanwhile fell 11% to $11.8 billion, down from the $13.26 billion it recorded in the same period last year.
‘Our strong performance in the first half of the year highlights the resiliency of our business even during the most challenging times,’ Pfizer CEO and chairman Albert Bourla said in its Q2 results.
Pfizer’s biopharma business had a particularly strong 2020, growing 9% operationally in the first six months of the year, driven by strong performances from many key brands, including Upjohn and Lyrica.
‘Upjohn faced the expected headwind of generic competition for Lyrica in the US that was partially offset by strong performance in China in second-quarter 2020,’ Bourla added.
‘We continue to progress toward a successful close of our transaction with Mylan, now expected in the fourth quarter of 2020’
Pfizer also marginally upgraded its full-year outlook, with the company expecting earnings per share (EPS) to come in between $2.85 to $2.95, up from its previous guidance of $2.82 to $2.92 EPS.
It also expects to generate $48.6 billion to $50.6 billion in 2020, up from its previous guidance of $48.5 billion to $50.5 billion.
S&P 500 keeps climbing
The S&P 500 has not looked back since it found support last week at 3200, moving smoothly higher over the past week, in sharp contrast to the lack of progress in the FTSE 100 and the DAX, according to Chris Beauchamp, chief market analyst at IG.
‘Further gains seem likely as the index begins to recover overnight losses, with the sequence of higher highs and higher lows firmly intact,’ he added.
How to trade stocks with IG
- Create an IG trading account or log in to your existing account
- Enter ‘Pfizer’ in the search bar and select it
- Choose your position size
- Click on ‘buy’ or ‘sell’ in the deal ticket
- Confirm the trade
This information has been prepared by IG, a trading name of IG Limited. In addition to the disclaimer below, the material on this page does not contain a record of our trading prices, or an offer of, or solicitation for, a transaction in any financial instrument. IG accepts no responsibility for any use that may be made of these comments and for any consequences that result. No representation or warranty is given as to the accuracy or completeness of this information. Consequently any person acting on it does so entirely at their own risk. Any research provided does not have regard to the specific investment objectives, financial situation and needs of any specific person who may receive it. It has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication. Although we are not specifically constrained from dealing ahead of our recommendations we do not seek to take advantage of them before they are provided to our clients.
CFDs are a leveraged products. CFD trading may not be suitable for everyone and can result in losses that exceed your initial deposit, so please ensure that you fully understand the risks involved.
Seize a share opportunity today
Go long or short on thousands of international stocks.
- Increase your market exposure with leverage
- Get spreads from just 0.1% on major global shares
- Trade CFDs straight into order books with direct market access
Live prices on most popular markets